Kyntra Bio (FRA:1FG0) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1FG0 Kyntra Bio Inc FRA:1FG0
51 GF Score
Price €5.70
GF Value €4.43
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:1FG0
51GF Score
Kyntra Bio Inc FRA:1FG0
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kyntra Bio (FRA:1FG0) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of €5.70 is trading 28.7% above its estimated GF Value™ of €4.43. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for FRA:1FG0:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €4.43 vs. price of €5.70 (28.7% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the FRA:1FG0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Other Exchanges KYNB:USAKYNB:Mexico0IL8:UK
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
51GF Score

Get the complete analysis for FRA:1FG0

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.70
Price
€4.43
GF Value